16.60
price down icon0.72%   -0.12
 
loading
Pharvaris Nv stock is traded at $16.60, with a volume of 189.85K. It is down -0.72% in the last 24 hours and down -3.88% over the past month. Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$16.72
Open:
$16.97
24h Volume:
189.85K
Relative Volume:
2.89
Market Cap:
$904.53M
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-5.879
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
+3.81%
1M Performance:
-3.88%
6M Performance:
-24.20%
1Y Performance:
-12.17%
1-Day Range:
Value
$16.26
$16.99
1-Week Range:
Value
$15.46
$16.99
52-Week Range:
Value
$11.51
$25.50

Pharvaris Nv Stock (PHVS) Company Profile

Name
Name
Pharvaris Nv
Name
Phone
-
Name
Address
-
Name
Employee
119
Name
Twitter
Name
Next Earnings Date
2024-08-05
Name
Latest SEC Filings
Name
PHVS's Discussions on Twitter

Compare PHVS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHVS
Pharvaris Nv
16.60 871.35M 0 -143.59M -119.47M -2.8236
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Sep-25-23 Initiated Wedbush Outperform
Aug-15-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-05-22 Initiated Bryan Garnier Buy
Sep-13-22 Resumed JMP Securities Mkt Outperform
Aug-23-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-22-22 Downgrade BofA Securities Neutral → Underperform
May-25-22 Initiated JMP Securities Mkt Outperform
Mar-02-21 Initiated BofA Securities Neutral
Mar-02-21 Initiated Morgan Stanley Overweight
Mar-02-21 Initiated Oppenheimer Outperform
Mar-02-21 Initiated SVB Leerink Outperform
View All

Pharvaris Nv Stock (PHVS) Latest News

pulisher
03:52 AM

Pharvaris (NASDAQ:PHVS) Shares Acquired by Deutsche Bank AG - Defense World

03:52 AM
pulisher
May 27, 2025

Northern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS) - Defense World

May 27, 2025
pulisher
May 24, 2025

How To Trade (PHVS) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 20, 2025

Cubist Systematic Strategies LLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World

May 20, 2025
pulisher
May 19, 2025

New Clinical Data Reveals Long-Term Success of Oral HAE Treatment Deucrictibant - Stock Titan

May 19, 2025
pulisher
May 18, 2025

Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened - Defense World

May 18, 2025
pulisher
May 18, 2025

Brokers Offer Predictions for Pharvaris FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs - Defense World

May 17, 2025
pulisher
May 17, 2025

Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00 - Defense World

May 17, 2025
pulisher
May 17, 2025

Research Analysts Issue Forecasts for Pharvaris Q2 Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

Pharvaris (NASDAQ:PHVS) Holdings Decreased by Barclays PLC - Defense World

May 16, 2025
pulisher
May 15, 2025

The Manufacturers Life Insurance Company Reduces Stake in Pharvaris (NASDAQ:PHVS) - Defense World

May 15, 2025
pulisher
May 15, 2025

Pharvaris (NASDAQ:PHVS) Shares Down 5.1% on Disappointing Earnings - Defense World

May 15, 2025
pulisher
May 14, 2025

Transcript : Pharvaris N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

PHVS Reports Decrease in Cash Reserves by March Quarter End | PH - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHV - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

(PHVS) Long Term Investment Analysis - news.stocktradersdaily.com

May 14, 2025
pulisher
May 13, 2025

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Pharvaris Hits Major FDA Milestone for HAE Drug Pipeline While Phase 3 Trials Show Strong Progress - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Pharvaris (PHVS) Expected to Announce Earnings on Wednesday - Defense World

May 13, 2025
pulisher
May 12, 2025

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - Stock Titan

May 12, 2025
pulisher
May 07, 2025

Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World

May 07, 2025
pulisher
May 03, 2025

When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com

May 03, 2025
pulisher
May 02, 2025

Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World

May 02, 2025
pulisher
May 02, 2025

Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World

May 02, 2025
pulisher
Apr 29, 2025

Cantor Fitzgerald Initiates Pharvaris at Overweight With $28 Price Target - marketscreener.com

Apr 29, 2025
pulisher
Apr 23, 2025

JMP reiterates Pharvaris stock with $55 target, positive outlook By Investing.com - Investing.com UK

Apr 23, 2025
pulisher
Apr 18, 2025

Where are the Opportunities in (PHVS) - news.stocktradersdaily.com

Apr 18, 2025
pulisher
Apr 12, 2025

What is Leerink Partnrs’ Forecast for Pharvaris Q1 Earnings? - The AM Reporter

Apr 12, 2025
pulisher
Apr 11, 2025

5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

What is Leerink Partnrs’ Estimate for Pharvaris Q1 Earnings? - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

Wedbush Issues Pessimistic Forecast for Pharvaris Earnings - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

What is Wedbush’s Forecast for Pharvaris FY2029 Earnings? - Defense World

Apr 10, 2025
pulisher
Apr 08, 2025

Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 08, 2025
pulisher
Apr 07, 2025

Pharvaris Reports 2024 Financial Results and Business Progress - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Pharvaris Accelerates HAE Drug Development: Phase 3 Trial Fully Enrolled, €281M War Chest - Stock Titan

Apr 07, 2025
pulisher
Apr 02, 2025

Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Apr 01, 2025

Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan

Apr 01, 2025
pulisher
Mar 12, 2025

(PHVS) Technical Data - news.stocktradersdaily.com

Mar 12, 2025
pulisher
Mar 03, 2025

Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan

Mar 03, 2025
pulisher
Mar 01, 2025

How to Take Advantage of moves in (PHVS) - Stock Traders Daily

Mar 01, 2025
pulisher
Feb 26, 2025

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance

Feb 26, 2025
pulisher
Feb 18, 2025

(PHVS) Trading Report - Stock Traders Daily

Feb 18, 2025
pulisher
Feb 17, 2025

Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat

Feb 17, 2025

Pharvaris Nv Stock (PHVS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Cap:     |  Volume (24h):